HeartBeam Secures 2 New U.S. Patents

HeartBeam has added two new U.S. patents to fortify its core intellectual property position.

The first patent protects IP around the company’s credit card-sized, cable-free 3D ECG device. The device has chest and finger electrodes to capture high-fidelity electrical signals in 3D by capturing three non-coplanar directions. This lets patients record symptoms as they occur.

The signals are then synthesized into a 12-lead ECG using a personalized transformational matrix. The 12-lead ECG synthesis software is under review with the U.S. Food and Drug Administration (FDA) and data from the pivotal VALID-ECG study supporting the submission was presented at last month’s Heart Rhythm Society conference.

The second patent covers HeartBeam’s rhythm analysis algorithm, which distinguishes between sinus rhythm, atrial fibrillation, and other arrhythmias using continuous signal input. The algorithm was engineered to operate on any cardiac monitoring system, wearables included.

The algorithm allows risk-based escalation by spotting anomalies during passive monitoring and prompting users to collect 3D ECG signals with the credit card-sized device, allowing synthesis of a 12-lead ECG.

These two patents bring the company’s total to 20 issued U.S. and international patents, two allowed patents, and 32 pending patents. The innovations pave the way for future capabilities like artificial intelligence (AI)-driven classification algorithms and ischemia detection.

“HeartBeam’s vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility,” said HeartBeam CEO Robert Eno. “The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care.”

Last month, the company also began collaborating with AccurKardia to make AccurKardia’s FDA-cleared AccurECG ECG analysis software available on HeartBeam’s devices.